HR+/HER2- Breast Cancer Market Report

Global and Region HR+/HER2- Breast Cancer Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Aug 01, 2022
  • PAGES：157
  • REPORT CODE：GMM954346
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of HR+/HER2- Breast Cancer market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of HR+/HER2- Breast Cancermarket, defines the market attractiveness level of HR+/HER2- Breast Cancer market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of HR+/HER2- Breast Cancer industry, describes the types of HR+/HER2- Breast Cancer market, the applications of major players and the market size, and deeply analyzes the current situation of the global HR+/HER2- Breast Cancer market and the development prospects and opportunities of HR+/HER2- Breast Cancer industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global HR+/HER2- Breast Cancer market in Chapter 13.

    By Player:

    • Eagle Pharmaceuticals

    • Merrimack Pharmaceuticals

    • Jiangsu HengRui Medicine

    • Syndax Pharmaceuticals

    • Merck

    • Roche Group

    • Odonate Therapeutics

    • GlaxoSmithKline

    • Radius Pharmaceuticals

    • Immunomedics

    • Bayer

    • Millennium Pharmaceuticals

    By Type:

    • CDK4/6 Inhibitors

    • PARP Inhibitors

    • PI3K Inhibitor

    • Others

    By End-User:

    • Hospitals

    • Cancer Center

    • Medical Research and Academic Institutions

    • Ambulatory Surgical Centers

    • Others

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 HR+/HER2- Breast Cancer Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 HR+/HER2- Breast Cancer Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 HR+/HER2- Breast Cancer Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 HR+/HER2- Breast Cancer Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise HR+/HER2- Breast Cancer Market Analysis and Outlook to 2022

    • 7.1 Global HR+/HER2- Breast Cancer Consumption (2017-2022)

    • 7.2 United States HR+/HER2- Breast Cancer Consumption (2017-2022)

    • 7.3 Europe HR+/HER2- Breast Cancer Consumption (2017-2022)

    • 7.4 China HR+/HER2- Breast Cancer Consumption (2017-2022)

    • 7.5 Japan HR+/HER2- Breast Cancer Consumption (2017-2022)

    • 7.6 India HR+/HER2- Breast Cancer Consumption (2017-2022)

    • 7.7 South Korea HR+/HER2- Breast Cancer Consumption (2017-2022)

    8 Region and Country-wise HR+/HER2- Breast Cancer Market Analysis and Outlook to 2028

    • 8.1 Global HR+/HER2- Breast Cancer Consumption Forecast (2022-2028)

    • 8.2 United States HR+/HER2- Breast Cancer Consumption Forecast (2022-2028)

    • 8.3 Europe HR+/HER2- Breast Cancer Consumption Forecast (2022-2028)

    • 8.4 China HR+/HER2- Breast Cancer Consumption Forecast (2022-2028)

    • 8.5 Japan HR+/HER2- Breast Cancer Consumption Forecast (2022-2028)

    • 8.6 India HR+/HER2- Breast Cancer Consumption Forecast (2022-2028)

    • 8.7 South Korea HR+/HER2- Breast Cancer Consumption Forecast (2022-2028)

    9 Global HR+/HER2- Breast Cancer Market Outlook by Types and Applications to 2022

    • 9.1 Global HR+/HER2- Breast Cancer Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global CDK4/6 Inhibitors Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global PARP Inhibitors Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global PI3K Inhibitor Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Others Consumption and Growth Rate (2017-2022)

    • 9.2 Global HR+/HER2- Breast Cancer Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospitals Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Cancer Center Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Medical Research and Academic Institutions Consumption and Growth Rate (2017-2022)

      • 9.2.4 Global Ambulatory Surgical Centers Consumption and Growth Rate (2017-2022)

      • 9.2.5 Global Others Consumption and Growth Rate (2017-2022)

    10 Global HR+/HER2- Breast Cancer Market Outlook by Types and Applications to 2028

    • 10.1 Global HR+/HER2- Breast Cancer Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global CDK4/6 Inhibitors Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global PARP Inhibitors Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global PI3K Inhibitor Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global Others Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global HR+/HER2- Breast Cancer Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Cancer Center Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Medical Research and Academic Institutions Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.4 Global Ambulatory Surgical Centers Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.5 Global Others Consumption Forecast and Growth Rate (2022-2028)

    11 Global HR+/HER2- Breast Cancer Import and Export Analysis (Top 5 Countries)

    • 11.1 Global HR+/HER2- Breast Cancer Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global HR+/HER2- Breast Cancer Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 HR+/HER2- Breast Cancer Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global HR+/HER2- Breast Cancer Market Competitive Analysis

    • 14.1 Eagle Pharmaceuticals

      • 14.1.1 Eagle Pharmaceuticals Company Details

      • 14.1.2 Eagle Pharmaceuticals HR+/HER2- Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Eagle Pharmaceuticals HR+/HER2- Breast Cancer Product and Service

    • 14.2 Merrimack Pharmaceuticals

      • 14.2.1 Merrimack Pharmaceuticals Company Details

      • 14.2.2 Merrimack Pharmaceuticals HR+/HER2- Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Merrimack Pharmaceuticals HR+/HER2- Breast Cancer Product and Service

    • 14.3 Jiangsu HengRui Medicine

      • 14.3.1 Jiangsu HengRui Medicine Company Details

      • 14.3.2 Jiangsu HengRui Medicine HR+/HER2- Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Jiangsu HengRui Medicine HR+/HER2- Breast Cancer Product and Service

    • 14.4 Syndax Pharmaceuticals

      • 14.4.1 Syndax Pharmaceuticals Company Details

      • 14.4.2 Syndax Pharmaceuticals HR+/HER2- Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Syndax Pharmaceuticals HR+/HER2- Breast Cancer Product and Service

    • 14.5 Merck

      • 14.5.1 Merck Company Details

      • 14.5.2 Merck HR+/HER2- Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Merck HR+/HER2- Breast Cancer Product and Service

    • 14.6 Roche Group

      • 14.6.1 Roche Group Company Details

      • 14.6.2 Roche Group HR+/HER2- Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Roche Group HR+/HER2- Breast Cancer Product and Service

    • 14.7 Odonate Therapeutics

      • 14.7.1 Odonate Therapeutics Company Details

      • 14.7.2 Odonate Therapeutics HR+/HER2- Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Odonate Therapeutics HR+/HER2- Breast Cancer Product and Service

    • 14.8 GlaxoSmithKline

      • 14.8.1 GlaxoSmithKline Company Details

      • 14.8.2 GlaxoSmithKline HR+/HER2- Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 GlaxoSmithKline HR+/HER2- Breast Cancer Product and Service

    • 14.9 Radius Pharmaceuticals

      • 14.9.1 Radius Pharmaceuticals Company Details

      • 14.9.2 Radius Pharmaceuticals HR+/HER2- Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 Radius Pharmaceuticals HR+/HER2- Breast Cancer Product and Service

    • 14.10 Immunomedics

      • 14.10.1 Immunomedics Company Details

      • 14.10.2 Immunomedics HR+/HER2- Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 Immunomedics HR+/HER2- Breast Cancer Product and Service

    • 14.11 Bayer

      • 14.11.1 Bayer Company Details

      • 14.11.2 Bayer HR+/HER2- Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)

      • 14.11.3 Bayer HR+/HER2- Breast Cancer Product and Service

    • 14.12 Millennium Pharmaceuticals

      • 14.12.1 Millennium Pharmaceuticals Company Details

      • 14.12.2 Millennium Pharmaceuticals HR+/HER2- Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)

      • 14.12.3 Millennium Pharmaceuticals HR+/HER2- Breast Cancer Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of HR+/HER2- Breast Cancer

    • Figure HR+/HER2- Breast Cancer Picture

    • Table Global HR+/HER2- Breast Cancer Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global HR+/HER2- Breast Cancer Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global HR+/HER2- Breast Cancer Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global HR+/HER2- Breast Cancer Consumption by Country (2017-2022)

    • Figure United States HR+/HER2- Breast Cancer Consumption and Growth Rate (2017-2022)

    • Table Europe HR+/HER2- Breast Cancer Consumption and Growth Rate (2017-2022)

    • Figure China HR+/HER2- Breast Cancer Consumption and Growth Rate (2017-2022)

    • Figure Japan HR+/HER2- Breast Cancer Consumption and Growth Rate (2017-2022)

    • Figure India HR+/HER2- Breast Cancer Consumption and Growth Rate (2017-2022)

    • Figure South Korea HR+/HER2- Breast Cancer Consumption and Growth Rate (2017-2022)

    • Figure Global HR+/HER2- Breast Cancer Consumption Forecast by Country (2022-2028)

    • Figure United States HR+/HER2- Breast Cancer Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe HR+/HER2- Breast Cancer Consumption Forecast and Growth Rate (2022-2028)

    • Figure China HR+/HER2- Breast Cancer Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan HR+/HER2- Breast Cancer Consumption Forecast and Growth Rate (2022-2028)

    • Figure India HR+/HER2- Breast Cancer Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea HR+/HER2- Breast Cancer Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global CDK4/6 Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Global PARP Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Global PI3K Inhibitor Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Hospitals Consumption and Growth Rate (2017-2022)

    • Figure Global Cancer Center Consumption and Growth Rate (2017-2022)

    • Figure Global Medical Research and Academic Institutions Consumption and Growth Rate (2017-2022)

    • Figure Global Ambulatory Surgical Centers Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global CDK4/6 Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global PARP Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global PI3K Inhibitor Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Cancer Center Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Medical Research and Academic Institutions Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Ambulatory Surgical Centers Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Table Global HR+/HER2- Breast Cancer Import by Region (Top 5 Countries) (2017-2028)

    • Table Global HR+/HER2- Breast Cancer Export by Region (Top 5 Countries) (2017-2028)

    • Table Eagle Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Eagle Pharmaceuticals HR+/HER2- Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)

    • Table Eagle Pharmaceuticals HR+/HER2- Breast Cancer Product and Service

    • Table Merrimack Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Merrimack Pharmaceuticals HR+/HER2- Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)

    • Table Merrimack Pharmaceuticals HR+/HER2- Breast Cancer Product and Service

    • Table Jiangsu HengRui Medicine (Foundation Year, Company Profile and etc.)

    • Table Jiangsu HengRui Medicine HR+/HER2- Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)

    • Table Jiangsu HengRui Medicine HR+/HER2- Breast Cancer Product and Service

    • Table Syndax Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Syndax Pharmaceuticals HR+/HER2- Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)

    • Table Syndax Pharmaceuticals HR+/HER2- Breast Cancer Product and Service

    • Table Merck (Foundation Year, Company Profile and etc.)

    • Table Merck HR+/HER2- Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)

    • Table Merck HR+/HER2- Breast Cancer Product and Service

    • Table Roche Group (Foundation Year, Company Profile and etc.)

    • Table Roche Group HR+/HER2- Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)

    • Table Roche Group HR+/HER2- Breast Cancer Product and Service

    • Table Odonate Therapeutics (Foundation Year, Company Profile and etc.)

    • Table Odonate Therapeutics HR+/HER2- Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)

    • Table Odonate Therapeutics HR+/HER2- Breast Cancer Product and Service

    • Table GlaxoSmithKline (Foundation Year, Company Profile and etc.)

    • Table GlaxoSmithKline HR+/HER2- Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)

    • Table GlaxoSmithKline HR+/HER2- Breast Cancer Product and Service

    • Table Radius Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Radius Pharmaceuticals HR+/HER2- Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)

    • Table Radius Pharmaceuticals HR+/HER2- Breast Cancer Product and Service

    • Table Immunomedics (Foundation Year, Company Profile and etc.)

    • Table Immunomedics HR+/HER2- Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)

    • Table Immunomedics HR+/HER2- Breast Cancer Product and Service

    • Table Bayer (Foundation Year, Company Profile and etc.)

    • Table Bayer HR+/HER2- Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bayer HR+/HER2- Breast Cancer Product and Service

    • Table Millennium Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Millennium Pharmaceuticals HR+/HER2- Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)

    • Table Millennium Pharmaceuticals HR+/HER2- Breast Cancer Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US